# Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study


Xiuning Le, MD, PhD,<sup>1</sup> Nicolas Girard, MD, PhD,<sup>2</sup> Pasi A. Jänne, MD, PhD,<sup>3</sup> Silvia Novello, MD, PhD,<sup>4</sup> Hye Ryun Kim, H, <sup>4</sup> Hye Ryun Daniel Shao-Weng Tan, PhD, MBBS, BSc,<sup>14</sup> Koichi Goto, MD, PhD,<sup>15</sup> Tine Descamps, PhD,<sup>17</sup> Rui Li, MS,<sup>17</sup> Paolo Grassi, MD,<sup>18</sup> Tae Min Kim, MD, PhD<sup>19</sup>

National University Cancer Institute, Singapore, Singapore; \*Chungbuk National University, Shanghai, China; <sup>11</sup>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; <sup>16</sup>Bayer plc, Reading, UK; <sup>17</sup>Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA; <sup>18</sup>Bayer S.p.A., Milan, Italy; <sup>19</sup>Seoul National University Hospital, Seoul, South Korea

#### Background: HER2 mutations in lung cancer



HER2 Y772\_A775dup (YVMA) insertion represents 75% of all *HER2* mutant lung cancer



#### Unmet needs in *HER2*-mutant NSCLC:


- Chemotherapy and ADCs are current options for patients with lung cancer harboring HER2 mutations<sup>1</sup>
- However, there is a need for the development of oral, targeted small molecule therapies to achieve greater efficacy and safety for patients with *HER2*-mutant NSCLC


ADC, antibody-drug conjugates; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer 1. Riely GJ, et al. *J Natl Compr Canc Natw*. 2024;22(4):249-274.

### Background: BAY 2927088

- BAY 2927088 is an oral, reversible tyrosine kinase inhibitor that potently inhibits activating HER2 (ERBB2) mutations in preclinical models<sup>1</sup>
- BAY 2927088 has shown encouraging preliminary anti-tumor activity in patients' manageable safety and with advanced NSCLC harboring HER2 mutations<sup>2</sup>
- The US FDA and Chinese NMPA have granted Breakthrough Therapy designations to BAY 2927088 for patients with unresectable or metastatic NSCLC with activating *HER2* mutations who have already received therapy<sup>3,4</sup>

#### In vivo antitumor efficacy of BAY 2927088 in the subcutaneous CTG-2543 (HER2 YVMA) PDX model of NSCLC






Here we report preliminary safety and efficacy of BAY 2927088 from the expansion phase of an ongoing open-label, first-in-human Phase I/II trial in patients with advanced HER2-mutant NSCLC naïve to HER2-targeted therapy

, human epidermal growth factor receptor 2; NMPA, National Medical Products Administration; NSCLC, non-small cell lung cancer; US, United States nall cell lung cancer. June 11, 2024. https://www.bayer.com/media/en-us/bayer-receives-breakthrough-therapy-designation-in-china-for-bay-2927088-in-high-unmet-need-patients-with-her2-mutant-non-

### SOHO-01 study design (NCT05099172)



phorts: <sup>b</sup>EGFR cohorts not presented here: <sup>c</sup>July 1, 2024 data cut-off. Dose optimization cohort (D1) ongoing: not shown

sease control rate; DoR, duration of response; EGFR, epidermal growth factor receptor; ex20ins, exon 20 insertion mutations; muts, mutations; HER2, human epidermal growth factor receptor 2 NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival


### SOHO-01 Cohort D: demographics and disease characteristics

	Cohort D ( <i>N</i> =44)*
Female, <i>n</i> (%)	28 (63.6)
Race, <i>n</i> (%)	
White	10 (22.7)
Asian	30 (68.2)
Not reported	4 (9.1)
Median age, years (range)	62.0 (29-82)
Baseline ECOG PS, <i>n</i> (%)	
0	19 (43.2)
1	25 (56.8)
Smoking habits at informed consent, <i>n</i> (%)	
Never	31 (70.5)
Former	11 (25.0)
Current	2 (4.5)
NSCLC histology, <i>n</i> (%)	
Squamous cell carcinoma, not otherwise specified	2 (4.5)
Adenocarcinoma, mixed or not otherwise specified	42 (95.5)
Median time since initial diagnosis, months (range) <sup>a</sup>	16.0 (3.9-77.2)
Median time since most recent progression / relapse to first administration of study treatment, months (range) <sup>b</sup>	1.5 (0-14.4)


\*One patient excluded from efficacy analysis dataset due to withdrawal of consent prior to post-baseline tu assessment

	Cohort D ( <i>N</i> =44)*	
HER2 mutations		
Y772_A775dup (YVMA) insertion	31 (70.5)	
Point mutations <sup>c</sup>	3 (6.8)	
Other	10 (22.7)	
Brain metastases at baseline <sup>d</sup>		
Yes	8 (18.2)	
No	36 (81.8)	
Number of previous systemic anti-cancer treatments, <i>n</i> (%)		
1	20 (45.5)	
2	10 (22.7)	
≥3	14 (31.8)	
Previous therapy <sup>e</sup>		
Previous platinum, no previous immunotherapy	17 (38.6)	
Previous platinum and immunotherapy	25 (56.8)	

Previously treated and asymptomatic brain metastases at baseline; <sup>e</sup>1 patient only had received immunotherapy ECOG PS, Eastern Cooperative Oncology Group performance status



ed CR or PR: <sup>©</sup>Patients with confirmed CR or confirmed PR or SD for ≥12 weeks: \*0%. SD: \*\*HER2 point mutations CI. confidence interval: CR. complete response: DCR. disease control rate: NR. no response: ORR. objective response rate: PD. progressive disease: PR. partial response: SD. stable disease



\*\**HER*2 point mutation CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease

DCR, disease control rate; DoR, duration of response; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival

We thank the patients and their families for participation in the SOHO-01 study. We thank the investigators and their team members at each of the 90 study sites across 16


(range 0.9-20.2)

observed in 14 patients (31.8%)

7.1 months (range 0.2-20.2)

treatment


## Subgroup analyses: *HER2* Y772\_A775dup insertion





9.7 months (95% CI 5.5, NE Median PFS 9.9 months (95% CI 6.9, N

Median DoR:



All evaluable patients CI, confidence interval; DCR, disease control rate; DoR, duration of response; NE, not estimable; ORR, objective response rate; PFS, progression-free surviva

# Safety and tolerability profile

ORR 90.0% DCR 96.7%

n (%)	All grades ( <i>N</i> =44)	Grade ≥3 ( <i>N</i> =44)
Any TRAE	42 (95.5)	19 (43.2)
Most common TRAEs occurring in ≥10% of patients	38 (86.4)	11 (25.0)
Diarrhea	38 (86.4)	11 (25.0)
Rash	19 (43.2)	0
Paronychia	11 (25.0)	0
Nausea	11 (25.0)	1 (2.3)
Vomiting	9 (20.5)	2 (4.5)
Dermatitis acneiform	8 (18.2)	0
Stomatitis	8 (18.2)	1 (2.3)
Dry skin	7 (15.9)	0
Increased aspartate aminotransferase	6 (13.6)	1 (2.3)
Decreased appetite	6 (13.6)	2 (4.5)
Increased amylase	5 (11.4)	0
Anemia	5 (11.4)	0
Increased lipase	5 (11.4)	0
Decreased weight	5 (11.4)	0
Pruritis	5 (11.4)	1 (2.3)

- Diarrhea was the most common TRAE, experienced by 38 patients (86.4%); principally grade 1 or 2
- 3 patients (6.8%) had TRAEs leading to treatment discontinuation
- Included corneal epithelial microcysts (n=1), reduced visual acuity (n=1), abnormal hepatic function (n=1), and dyspnea (*n*=1)
- 14 patients (31.8%) had dose reductions due to TRAEs<sup>a</sup>
- 5 patients (11.4%) had serious TRAEs

- Included diarrhea (n=1), duodenitis (n=1), vomiting (n=1), and abnormal hepatic function (n=2)

• There were no grade 4 TRAEs and 1 grade 5 event (dyspnea); no reports of ILD/pneumonitis

diarrhea (n=6), abnormal hepatic function (n=2), increased alanine aminotransferase (n=2), decreased appetite (n=2)

- The safety profile of BAY 2927088 was manageable and consistent with previous reports
- These data support the ongoing investigation of BAY 2927088 in patients with advanced NSCLC harboring HER2 mutations
- Ongoing phase III SOHO-02 trial (see Goto et al., 2024 WCLC, EP.12H.08)

D. interstitial lung disease: TRAE. treatment-related adverse event



Scan this QR code to download an electronic version of this poster.